Is Ekimas Corp (NORD) Stock a Good Investment?
Learn more about Ekimas Corp's (NORD) stock grades for Growth and determine whether this Investment Holding Companies stock meets your investment needs.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nordicus Partners Corporation, a biotech company specializing in developing breakthrough therapeutics for diseases with unmet medical needs in the United States. It develops medicines supporting oral health. The company was formerly known as EKIMAS Corporation and changed its name to Nordicus Partners Corporation in May 2023. Nordicus Partners Corporation was founded in 1993 and is based in Beverly Hills, California.
Commentary & Analysis
Financial Summary
| Share Statistics | NORD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $78.4 | $237.5 | 20% |
|
| Shares Out (Mil) | 19.2 | 53.9 | 30% |
|
| Institutional Ownership | na | 93.1% | na |
|
| Float (Mil) | na | 41.4 | na |
|
| Beta | -0.48 | 0.95 | 2% |
|
| Avg Daily Volume (000s) | 10 | 628 | 17% |
|
| Price Change (52-week) |
34.4% | 49.0% | 78% |
|
| Growth | NORD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.4% | na |
|
| Net Income (5yr) | (109.1%) | (10.2%) | 2% |
|
| EPS (5yr) | na | 15.7% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | NORD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($5) | ($44) | 33% |
|
| EPS (TTM) | ($0.273) | ($1.600) | 32% |
|
| Operating Cash Flow (TTM) (Mil) | ($4) | ($33) | 26% |
|
| Net Cash Flow (TTM) (Mil) | $0 | $2 | 43% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $78 | $174 | 19% |
|
| Valuation | NORD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.26 | 2.27 | 34% |
|
| P/E | na | 19.7 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | NORD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (6.8%) | (47.7%) | 28% |
|
| ROE | (8.1%) | (55.0%) | 29% |
|
| Liabilities to Assets | 15.9% | 29.4% | 10% |
|
| F-Score | 3 | 2 | 18% |
|
Nordicus Partners Corporation did not pass any screens on 10/12/2026.
